|
市場調查報告書
幹細胞業界的最新動向：技術革新對未來的影響和商業環境的評價
Advances in the Stem Cell Industry: The future impact of innovation, and an evaluation of the commercial landscape
|
幹細胞業界的最新動向：技術革新對未來的影響和商業環境的評價 是由出版商Business Insights在2009年10月所出版的。
這份英文市場調查報告書包含162 pages 價格從美金3835起跳。
世界幹細胞市場的銷售在2008年達到4億1000萬美金，預計2012年達到26億8000萬美金、2014年會達到51億美金。
本報告書包括：幹細胞的基本資訊和世界幹細胞市場的概要說明，研究開發動向、藥品開發及疾病治療的應用、商品化的動向等，並同時有企業的簡介。內容綱要摘記如下：
實施概要
第1章 背景
第2章 幹細胞的研究開發：範圍和現況
第3章 商業環境
第4章 業界的動向
第5章 附錄
圖表
Abstract
An important milestone in the development of stem cell technology occurred in
2007, when researchers induced human cells into a stem cell state using
defined genetic factors. These cells are now known as induced pluripotent stem
(IPS) cells; they offer an alternative to using embryonic stem cells. This
report takes the implications of IPS cells and other developments into
account. Some essential technologies are already in place and stem-cell based
therapies have already begun to appear in the marketplace. The stem cell
market is already divided into three segments - cell-based treatments,
umbilical cord blood banking, and the use of stem cells to evaluate the
efficacy and safety of new drugs developed by other methods. Global sales
reached $410 million in 2008, and will grow to $2.68 billion by 2012. This
growth will reach a projected $5.1 billion in 2014, providing a realistic, and
even cautious forecast of the commercial potential these segments.
Table of Contents
Executive summary
- Background
- Stem cell research and development: scope and status
- Commercial landscape
- Industry landscape
Chapter 1 - Background
- Introduction
- The building blocks of life
- About stem cells
- Potency
- Stem cell division
- Stem cell research
- Current status of knowledge
- Embryonic stem cells
- Growth and identification of ESCs
- Stimulating ESCs to differentiate
- Adult stem cells
- Cord blood stem cells
- Induced pluripotent stem cells
- Nuclear reprogramming
- Ethical and regulatory issues
- Situation in the US
- European regulations
Chapter 2 - Stem cell research and development: scope and status
- Practical applications of stem cells
- Disease treatment
- Amyotrophic lateral sclerosis
- Parkinson' s disease
- Spinal cord injury
- Alzheimer' s disease
- Cancer
- Heart disease
- Peripheral arterial disease
- Type 1 diabetes
- Liver failure
- Graft-versus-host disease
- Stem cell models: applications in drug discovery
- Screening studies
- Toxicity studies
- Practical benefits
- Some skepticism remains
Chapter 3 - Commercial landscape
- Summary
- Resisting the hyperbole
- Market realities
- Cell-based therapy market
- Autologous SC therapy
- Allogeneic SC therapy
- Cord blood banks
- Market drivers
- Market
- Global market estimates and forecasts
- Global market by use
- Global market by country share
- Embryo vs. adult stem cells
- Investment opportunities
- Choosing a viable business model
- Matching the model to the circumstance
- Autologous therapy models
- Allogeneic therapy models
Chapter 4 - Industry landscape
- Company profiles
- Aastrom Biosciences, Inc.
- Advanced Cell Technology, Inc.
- Overview
- Pipeline
- Collaboration
- Aldagen
- Overview
- Pipeline
- Collaboration
- Angioblast Systems, Inc.
- Athersys, Inc.
- Overview
- Pipeline
- Collaboration
- Financials
- Bioheart, Inc.
- Bionet
- Brainstorm Cell Therapeutics
- Capricor, Inc.
- Overview
- Pipeline
- Collaboration
- Cardio3 BioSciences SA
- Cellcyte Genetics
- Overview
- Pipeline
- Collaboration
- Cellerix SA
- CellGenix Technologie Transfer
- Cytori Therapeutics, Inc.
- Entest BioMedical, Inc.
- ES Cell International
- EvoStem Finland Oy
- Fate Therapeutics, Inc.
- Genzyme
- Geron
- Healtheuniverse, Inc.
- Innovacell Biotechnologie AG
- International Stem Cell Corporation (ISCO)
- iPierian, Inc.
- Ixion Biotechnology, Inc.
- Karocell Tissue Engineering AB
- MedCell Bioscience Ltd
- MediStem, Inc.
- Mesoblast Limited
- Nephrogenix
- Neuralstem, Inc.
- Overview
- Pipeline
- Collaboration
- OncoStem Pharma
- Novocell, Inc.
- NuVasive, Inc.
- Osiris Therapeutics, Inc.
- Overview
- Pipeline
- Collaboration
- Financials
- Pharmicell Europe GmbH
- PrimeGen Biotech
- Opexa Therapeutics
- Overview
- Financing
- Financials
- Plureon
- Overview
- Pipeline
- Collaboration
- Proteonomix, Inc.
- Regenerative Sciences, Inc.
- ReNeuron
- Shenzhen Beike
- Stematix, Inc.
- StemCells, Inc.
- Stem Cell Therapeutics
- Stem Cell Therapy International
- Stemedica Cell Technologies, Inc.
- Stempeutics Research Pvt. Ltd.
- t2cure GmbH
- TICEBA GmbH
- Tristem
Chapter 5 - Appendix
- Methodology
- Glossary
- Index
List of Figures
- Figure 1.1: Early embryonic development and later differentiation
- Figure 1.2: Stem cell division
- Figure 1.3: Induced pluripotent stem cells
- Figure 2.4: Stem cell opportunities in disease treatment and R&D
- Figure 3.5: Forces affecting the stem cell market
- Figure 3.6: Key challenges faced when developing autologous therapy
- Figure 4.7: Type and number of regenerative medicine organizations
List of Tables
- Table 3.1: Global stem cell market ($m), 2008-14
- Table 3.2: Potential US patient populations for cell-based therapies
- Table 3.3: Stem cell market by main uses ($m), 2008-14
- Table 3.4: Country breakdown of stem cell market ($m), 2008-14
- Table 3.5: Leading cell-based regenerative medicine products
|
